Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 899376 | ISIN: US5147661046 | Ticker-Symbol: LDE
Frankfurt
06.06.25 | 08:01
5,850 Euro
-1,68 % -0,100
1-Jahres-Chart
LIFECORE BIOMEDICAL INC Chart 1 Jahr
5-Tage-Chart
LIFECORE BIOMEDICAL INC 5-Tage-Chart
RealtimeGeldBriefZeit
5,9006,10006.06.
5,9006,15006.06.

Aktuelle News zur LIFECORE BIOMEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.05.Lifecore Biomedical Appoints CCO1
27.05.Lifecore appoints new chief commercial officer to drive growth1
27.05.Lifecore Biomedical, Inc.: Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer94Mr. DaFonseca Possesses Nearly 30 Years of Broad Drug Development Experience, including More than 15 Years Leading High Performing CDMO Sales Organizations Will Leverage Deep Pharma Services Expertise...
► Artikel lesen
22.05.What Makes Lifecore Biomedical (LFCR) a Beneficiary of the Trade Policies?3
LIFECORE BIOMEDICAL Aktie jetzt für 0€ handeln
21.05.Lifecore stock gains on Outperform rating by William Blair1
16.04.Lifecore Biomedical, Inc.: Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)81CHASKA, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore") a fully integrated contract development and manufacturing organization ("CDMO"), today announced...
► Artikel lesen
14.04.Lifecore Biomedical Taps Thomas Salus as Chief Legal & Administration Officer1
14.04.Lifecore Biomedical, Inc.: Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer1
10.04.LIFECORE BIOMEDICAL, INC. \DE\ - 8-K, Current Report1
04.04.Lifecore Biomedical targets 12% revenue CAGR and expanded CDMO pipeline by 20271
03.04.LIFECORE BIOMEDICAL, INC. \DE\ - 10-Q, Quarterly Report2
03.04.Lifecore Biomedical GAAP EPS of -$0.47 misses by $0.32, revenue of $35.15M beats by $1.92M1
03.04.Lifecore Biomedical, Inc.: Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate Update158-- Recorded Revenues of $35.2 Million for Q3 Fiscal 2025 -- -- Signed Multiple Development Agreements with New and Existing Customers -- -- Strengthened Balance Sheet through Sale of Excess Capital...
► Artikel lesen
03.04.LIFECORE BIOMEDICAL, INC. \DE\ - 8-K, Current Report2
27.03.Lifecore Biomedical, Inc.: Lifecore Biomedical to Report Financial Results for Third Quarter of Fiscal 2025 on April 3, 20251
17.03.Humanetics Selects Lifecore Biomedical to Deliver CDMO Services for BIO 3001
17.03.Lifecore Biomedical, Inc.: Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome1
17.01.Lifecore Biomedical, Inc.: Lifecore Biomedical Announces Special Stockholder Meeting2
17.01.LIFECORE BIOMEDICAL, INC. \DE\ - 8-K, Current Report-
07.01.Lifecore Biomedical to sell multi-purpose 10-head isolator filler1
Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1